The Impact of Cilostazol in Refractory Vasospastic Angina
Cardiology · 2025
DOI: 10.1159/000544943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology, 2025. Verfasst von Richard Z Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Cilostazol, Coronary Vasospasm, Angina Pectoris, Vasodilator Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Refractory vasospastic angina (VSA) includes patients with disabling angina despite maximally tolerated calcium channel blocker and nitrate therapy. Randomised clinical trial evidence confirms the efficacy of cilostazol in refractory VSA, yet its use in real-world clinical practice is limited. This study evaluated the impact of cilostazol therapy on patient-reported outcomes in patients with refractory VSA.
Methods
Between June 2016 and May 2022, 15 consecutive refractory VSA patients were initiated on cilostazol (50mg twice daily), with baseline and 3-month responses assessed via the Seattle Angina Questionnaire (SAQ). The primary outcome was a clinically significant reduction in angina frequency (ie >10-point improvement in SAQ angina frequency score) at 3 months.
Results
A clinically significant reduction in angina frequency was reported in 13 patients (86%) at 3-months, with 3 (20%) becoming angina free. Moreover, over 3 months, median SAQ scores improved for angina frequency (25 [IQR 15,46] to 75 [30,82]), physical limitation (53 [44,67] to 83 [56,92]), and quality-of-life (17 [4,29] to 50 [35,58]). Additionally, a 54% reduction in angina-related emergency department presentations and 50% reduction in angina-related hospital admissions was noted. Minor medication-related adverse effects were experienced by 3 patients, with no serious adverse effects noted. Cilostazol was continued in 14 patients (93%) beyond the 3-month follow-up period.
Conclusions
In patients with refractory VSA, cilostazol is well tolerated, improves patient-reported outcomes, reduces healthcare utilisation, and thus is an effective therapy in real-world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
- Basil Hetzel Institute for Translational Health Research, Adelaide, South Australia, Australia.
- Department of Cardiology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia, john.beltrame@adelaide.edu.au.
- Basil Hetzel Institute for Translational Health Research, Adelaide, South Australia, Australia, john.beltrame@adelaide.edu.au.
- Department of Cardiology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia, john.beltrame@adelaide.edu.au.
Zitieren
APA
Lin, R. Z., Tavella, R., Shakib, S., & Beltrame, J. F. (2025). The Impact of Cilostazol in Refractory Vasospastic Angina. Cardiology. https://doi.org/10.1159/000544943
Vancouver
Lin RZ, Tavella R, Shakib S, Beltrame JF. The Impact of Cilostazol in Refractory Vasospastic Angina. Cardiology. 2025. doi:10.1159/000544943
BibTeX
@article{Lin2025,
author = {Lin, Richard Z and Tavella, Rosanna and Shakib, Sepehr and Beltrame, John F},
title = {The Impact of Cilostazol in Refractory Vasospastic Angina},
journal = {Cardiology},
year = {2025},
doi = {10.1159/000544943}
}
EUVIMED